Back to search results

Phase 1 Study of Itraconazole and ABBV-722 in Healthy Adults

This study is looking for healthy adult volunteers to understand how a common antifungal medication, itraconazole, affects a new drug called ABBV-722. Researchers want to see how ABBV-722 is absorbed and processed by the body when taken with itraconazole. This helps them understand how these drugs might interact. You could be eligible if you are between 18 and 65 years old and are generally healthy, based on medical checks. The study aims to enroll 12 participants. The current recruitment status is unclear.

Study design
This is a Phase 1 interventional study planning to enroll 12 healthy adult participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken up to Day 8 in Period 1 and up to Day 14 in Period 2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07599761

A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

Active, Not Recruiting
PHASE1Ages 18–65InterventionalBasic science
AbbVie
~12 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:ABBV-722Itraconazole

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Observed Plasma Concentration (Cmax) of ABBV-722
Measured over Up to Day 8 in Period 1 and Up to Day 14 in Period 2
+6 more outcomes measured

Conditions

Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07599761

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Acpru /Id# 282143

    Grayslake, Illinoisno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Laboratory values meet the criteria specified in the protocol.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).

Exclusion

History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration.
Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment.
Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.

What this trial measures

  • Maximum Observed Plasma Concentration (Cmax) of ABBV-722Up to Day 8 in Period 1 and Up to Day 14 in Period 2

    Cmax of ABBV-722

  • Time to Cmax (Tmax) of ABBV-722Up to Day 8 in Period 1 and Up to Day 14 in Period 2

    Tmax of ABBV-722

  • Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722Up to Day 8 in Period 1 and Up to Day 14 in Period 2

    AUCt of ABBV-722

  • Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722Up to Day 8 in Period 1 and Up to Day 14 in Period 2

    AUCinf of ABBV-722

  • Terminal Phase Elimination Rate Constant (β) of ABBV-722Up to Day 8 in Period 1 and Up to Day 14 in Period 2

    β of ABBV-722

  • Terminal Phase Elimination Half-Life (t1/2) of ABBV-722Up to Day 8 in Period 1 and Up to Day 14 in Period 2

    t1/2 of ABBV-722

  • Number of Participants with Adverse Events (AEs)Up to Approximately 45 Days

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.